Dr. Liu was awarded on November 12, 2022, as part of the CABS 23rd Annual BioPacific Conference entitled, “Resilience and Ingenuity – Embracing Opportunities in a New Normal”. The theme this year reflects economic and supply chain turbulences that have presented both new challenges and opportunities for the life sciences and biopharmaceutical industries, despite ongoing COVID-19. For the past 24 years, CABS has been one of the largest and most active non-profit biopharmaceutical organizations in western United States.
Read MoreAt the SAPA conference, HanchorBio presented the company’s proprietary Fc-based designer biologics (FBDB™) platform led to biological products that targeting phagocytosis checkpoint blockade and incorporating both innate and adaptive immune responses to treat patients with cancer. During the conference, HanchorBio ended with dozens of one-on-one meetings with national and international partners and multiple possible leads for in-licensing, research collaborations, or commercial right out-licensing conducted by Dr. Yi Du (Sr. Director of Business Development). These discussions mainly focused on advancing science and innovation on the development of anti-tumor immunotherapies to eliminate tumor immune escape.
Read MoreAugust 5th, 2022 – HanchorBio Inc. (“HanchorBio”), a biotechnology company pioneering the development of next-generation immunotherapies, today announced the successful completion of approximately US$20 million Series-A financing. The proceeds will enable HanchorBio to further expand and accelerate its growing pipeline of the proprietary Fc-based designer biologics (FBDB™) and to support the anticipated investigational new drug (IND)-enabling good laboratory practice (GLP) toxicology studies, IND submissions, and the first part of phase 1 clinical trials.
2022年8月5日，漢康生技——一家致力於成為開發下一代免疫療法先驅者的生物技術公司，宣佈成功完成了約計2000萬美金的A輪融資交割。本次A輪融資的資金將使漢康生技能夠進一步擴大和加速其不斷增長的專有“基於Fc設計的生物製藥（FBDB™）”管線研發進程，並將進一步支援擬申報新藥在臨床前研究階段（IND-enabling）的GLP毒理研究、新藥申報以及後續第一部分的臨床I期試驗。